Corona Remedies Q1FY27 net profit rises 29.5% to ₹601M on revenue surge
Corona Remedies posted strong Q1FY27 results with net profit rising 29.5% to ₹601M and revenue growing 20.6% to ₹4.22B. EBITDA margins expanded to 22.04%, reflecting better cost control and operational leverage.
*this image is generated using AI for illustrative purposes only.
Corona Remedies reported a significant improvement in its first-quarter financial performance for FY27, with net profit rising 29.5% year-on-year to ₹601 million. The pharmaceutical company’s revenue from operations grew by 20.6% to ₹4.22 billion, reflecting strong demand and operational efficiency. This growth trajectory underscores the company's ability to scale profitability while expanding its top line in a competitive market.
The Board of Directors, at its meeting held on July 31, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee on July 30, 2026, and subjected to a limited review by Walker Chandiok & Co LLP, the statutory auditors of the company, who issued an unmodified review conclusion. The filing was made in compliance with Regulation 33 read with Regulation 47(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance Highlights
Corona Remedies demonstrated robust growth across key financial metrics in Q1FY27 compared to the corresponding period of the previous fiscal year. Revenue from operations increased from ₹3.5 billion to ₹4.22 billion. Concurrently, net profit after tax rose from ₹464 million to ₹601 million. The following table details the key financial parameters:
| Metric | Q1FY27 (₹ Million) | Q1FY26 (₹ Million) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 4,220 | 3,500 | +20.6% |
| Net Profit After Tax | 601 | 464 | +29.5% |
| EBITDA | 930 | 710 | +31.0% |
| EBITDA Margin | 22.04% | 20.49% | +155 bps |
Operating Efficiency and Margins
The company’s operating leverage improved notably in the quarter. EBITDA grew by 31.0% to ₹930 million, outpacing revenue growth. This resulted in an expansion of the EBITDA margin by 155 basis points to 22.04%, up from 20.49% in Q1FY26. The margin expansion indicates enhanced cost management and higher value realization from its product portfolio.
What the Numbers Show
The divergence between revenue growth (20.6%) and net profit growth (29.5%) highlights improved operational efficiency. The simultaneous expansion in EBITDA margins suggests that fixed costs are being spread over a larger revenue base, or variable costs have decreased as a percentage of sales. This structural improvement in profitability provides a stronger foundation for future cash flows and potential reinvestment in research and development or capacity expansion.
Regulatory Disclosures
The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The full format of the unaudited financial results is available on the company’s website and the stock exchanges’ websites. No exceptional items were reported for the quarter. The company continues to operate in compliance with all applicable listing obligations.
Historical Stock Returns for Corona Remedies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.37% | +3.40% | +6.68% | +41.89% | +45.91% | +45.91% |
How does Corona Remedies plan to sustain the 155 bps EBITDA margin expansion amidst potential raw material cost inflation in FY27?
What specific capacity expansion or R&D initiatives is the company prioritizing with the increased cash flows from improved profitability?
Which therapeutic segments or geographic markets contributed most significantly to the 20.6% revenue growth, and are these trends expected to persist?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
